Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Diabetes, Obesity and Metabolism Année : 2021

Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study

1 CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers
2 Service d'endocrinologie, diabétologie et nutrition [CHU Bichat]
3 AMU - Aix Marseille Université
4 C2VN - Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research
5 ITX - ITX - unité de recherche de l'institut du thorax
6 CHU Nantes - Centre Hospitalier Universitaire de Nantes
7 CIC Nantes - Centre d’Investigation Clinique de Nantes
8 CHU d'Angers [Département Urgences]
9 CHU Angers - Centre Hospitalier Universitaire d'Angers
10 GHH - Groupe Hospitalier du Havre Hôpital Jacques Monod (MONTIVILLIERS)
11 CRESTIC - Centre de Recherche en Sciences et Technologies de l'Information et de la Communication - EA 3804
12 HIA Begin - Hôpital d'Instruction des Armées Begin [Saint-Mandé, France]
13 C3M - Centre méditerranéen de médecine moléculaire
14 UREN - Unité de Recherche en Epidémiologie Nutritionnelle
15 Centre Hospitalier Le Mans (CH Le Mans)
16 Centre hospitalier Saint-Joseph [Paris]
17 Hôpital Claude Huriez [Lille]
18 CIC Montpellier
19 CHU ST-E - Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne]
20 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
21 Service de diabétologie [CHU Cochin]
22 CIC - Centre d'Investigation Clinique [Rennes]
23 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
24 CHU Nancy - Centre Hospitalier Universitaire de Nancy
25 Hôpitaux de Chartres [Chartres]
26 CarMeN - Cardiovasculaire, métabolisme, diabétologie et nutrition
27 Service d'endocrinologie, diabétologie et maladies métaboliques [Rouen]
28 Service Endocrinologie - Diabétologie [CHU Caen]
29 Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]
30 CIC 1402 - CIC Poitiers – Centre d'investigation clinique de Poitiers
31 CRSA - Centre de Recherche Saint-Antoine
32 I2MC - Institut des Maladies Métaboliques et Cardiovasculaires
Christine Coffin‐boutreux
  • Fonction : Auteur
Bénédicte Fremy
  • Fonction : Auteur
Florence Galtier
Etienne Larger
Stéphanie Laugier‐robiolle
  • Fonction : Auteur
Nathanaëlle Montanier
  • Fonction : Auteur
Isabelle Moura
  • Fonction : Auteur
Pierre Serusclat
  • Fonction : Auteur

Résumé

Aim: To investigate the association between routine use of dipeptidyl peptidase-4 (DPP-4) inhibitors and the severity of coronavirus disease 2019 (COVID-19) infection in patient with type 2 diabetes in a large multicentric study. Materials and Methods: This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID-19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP-4 inhibitors users vs. non-users) and were used in multivariable logistic regression models to estimate the average treatment effect in the treated as inverse probability of treatment weighting (IPTW). Results: Five hundred and ninety-six participants were under DPP-4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non-users of DPP-4 inhibitors (27.7% vs. 28.6%; p = .68). In propensity analysis, the IPTW-adjusted models showed no significant association between the use of DPP-4 inhibitors and the primary outcome by Day 7 (OR [95% CI]: 0.95 [0.77-1.17]) or Day 28 (OR [95% CI]: 0.96 [0.78-1.17]). Similar neutral findings were found between use of DPP-4 inhibitors and the risk of tracheal intubation and death. Conclusions: These data support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued.
Fichier principal
Vignette du fichier
Roussel et al-2021-Use of Dipeptidyl Peptidase-4 inhibitors and prognosis of COVID-19 in.pdf (1.7 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03246543 , version 1 (02-06-2021)

Identifiants

Citer

Ronan Roussel, Patrice Darmon, Matthieu Pichelin, Thomas Goronflot, Yawa Abouleka, et al.. Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. Diabetes, Obesity and Metabolism, 2021, 23 (5), pp.1162-1172. ⟨10.1111/dom.14324⟩. ⟨hal-03246543⟩
221 Consultations
145 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More